Stay updated with breaking news from Therapeutic doses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Magic mushrooms can treat medication-resistant depression—but are they safe? medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
A study in JAMA Network Open examined the acute adverse effects of therapeutic doses of psilocybin for treating depression and anxiety, focusing on its safety profile by assessing the occurrence of immediate side effects like headache, nausea, and elevated blood pressure among others. ....
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopic dermatitis - Management to host conference call and webcast today, 1 March, at 8am ET / 9pm SGT SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim unblinded data from the three dose cohorts of its ongoing randomised, double-blind placebo controlled multiple ascending dose study of ASLAN004 for the treatment of moderate to severe atopic dermatitis (AD). ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potenti ....